<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Neuromidin (ipidacrin) was administered to 41 patients, aged 51-79 years, with mild <z:hpo ids='HP_0100543'>cognitive impairment</z:hpo> (MSI) (19) and vascular <z:hpo ids='HP_0000726'>dementia</z:hpo> (22) </plain></SENT>
<SENT sid="1" pm="."><plain>The drug was prescribed in increasing dosages from 10 to 40 mg during 6 months (a dosage of 40 mg was administered from the 4th week of the treatment) </plain></SENT>
<SENT sid="2" pm="."><plain>Cognitive functioning was assessed using some clinical scales (CGI, MMSE, GDS etc) and common neuropsychological tests at the base-line and on the 3rd and 6th month of the treatment </plain></SENT>
<SENT sid="3" pm="."><plain>A statistically significant therapeutic effect of neuromidin was revealed in both types of <z:e sem="disease" ids="C0009241" disease_type="Mental or Behavioral Dysfunction" abbrv="">cognitive disorders</z:e>, with the maximal improvement on the first 3 months and further maintenance of the effect </plain></SENT>
<SENT sid="4" pm="."><plain>The most distinct dynamics was observed for memory, attention, abstract reasoning, constructive abilities and general mental activity </plain></SENT>
<SENT sid="5" pm="."><plain>The drug was well tolerated </plain></SENT>
</text></document>